Has Maria Nieto, MD received payments from drug or device companies?

Yes. Drug and device makers reported $7,133 in general payments to Maria Nieto, MD across 4 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Maria Nieto, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Maria Nieto, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Maria Nieto, MD

Medical Oncology · New York, NYNPI 1548496326

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $7,100 of the $7,133 with a category attached, or 99.5%. E.r. Squibb & Sons, L.L.C. accounts for 99.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $7,100, more than ten times the $14 reported in 2019. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.

$7,133in general payments, 2019–2025

Across 4 payments — averaging $1783.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

E.r. Squibb & Sons, L.L.C.$7K
Boston Scientific$19
Hologic Sales And Service, LLC$14

$171,880in research payments, 2019–2025

Across 8 payments — averaging $21,485 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bristol Myers Squibb$136K
E.r. Squibb & Sons, L.L.C.$35K

What the payments were for

Consulting fees$7,100100%
Food & beverage$330%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
E.r. Squibb & Sons, L.L.C.	2	$7,100
Boston Scientific	1	$19
Hologic Sales And Service, LLC	1	$14

How this compares

$7,133 in reported general payments places this provider in the 50th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$86,830

Medicare patients

280

Services billed

544

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RevlimidLenalidomide	39	$666,862
JakafiRuxolitinib Phosphate	25	$411,723
ImbruvicaIbrutinib	23	$406,324
SprycelDasatinib	22	$375,725
BrukinsaZanubrutinib	26	$359,444
JaypircaPirtobrutinib	12	$256,067
PromactaEltrombopag Olamine	18	$148,815
EliquisApixaban	120	$78,174
Imatinib Mesylate	32	$53,210
Posaconazole	28	$36,401
XareltoRivaroxaban	17	$12,120
Anagrelide Hcl	22	$2,321
Hydroxyurea	94	$1,317
Entecavir	32	$1,172
Midodrine Hcl	11	$1,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sprycel	$7,100	$375,72522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 498 medical oncology providers in New York.

Other medical oncology in New York

Craig ThompsonNew York$4.8M
Andrew SeidmanNew York$1.3M
Joshua RichterNew York$971K
Edward GelmannNew York$944K
Ghassan Abou-AlfaNew York$825K
Miguel PeralesNew York$769K
Komal JhaveriNew York$642K
Joshua BrodyNew York$492K
Aiwu HeNew York$445K
Raajit RampalNew York$418K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →